A Review of Biomarkers for Alzheimer’s Disease in Down Syndrome

被引：13
作者：
Lee N.-C. [1 ]
Chien Y.-H. [1 ]
Hwu W.-L. [1 ]
机构：
[1] Department of Medical Genetics and Pediatrics, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei
来源：
Neurology and Therapy | 2017年 / 6卷 / Suppl 1期
关键词：
Alzheimer’s disease; Amyloid; Biomarker; Down syndrome; Tau;
D O I：
10.1007/s40120-017-0071-y
中图分类号：
学科分类号：
摘要：
Down syndrome (Trisomy 21; DS) is a unique disease known to be associated with early-onset Alzheimer’s disease (AD). The initial presentation of AD in DS is usually difficult to recognize, owing to the underlying intellectual disabilities. Using biomarkers as a prediction tool for detecting AD in at-risk people with DS may benefit patient care. The objective of this review is to discuss the utility of biomarkers in DS on the basis of the pathophysiology of the disease and to provide an update on recent studies in this field. Only through the comprehensive assessment of clinical symptoms, imaging studies, and biomarker analyses can people with DS who are at risk for AD be diagnosed early. Studies for biomarkers of AD in DS have focused on the common pathophysiology of AD in people with DS and in the general population. The most extensively studied biomarkers are amyloid and tau. Owing to the nature of amyloid precursor protein overproduction in DS, the baseline β-amyloid (Aβ) plasma levels are higher than those in controls. Hence, the changes in Aβ are considered to be a predictive marker for AD in DS. In addition, other markers related to telomere length, neuroinflammation, and methylation have been investigated for their correlation with AD progression. Future studies including different ethnic groups may be helpful to collect sufficient data to monitor drug safety and efficacy, stratify patients at risk for AD, and quantify the benefit of treatment. © 2017, The Author(s).
引用
收藏
页码：69 / 81
页数：12
相关论文
共 79 条
[51]  
Vandenberghe R., Adamczuk K., Dupont P., Laere K.V., Chetelat G., Amyloid PET in clinical practice: its place in the multidimensional space of Alzheimer’s disease, Neuroimage Clin., 2, pp. 497-511, (2013)
[52]  
Sabbagh M.N., Fleisher A., Chen K., Rogers J., Berk C., Reiman E., Et al., Positron emission tomography and neuropathologic estimates of fibrillar amyloid-beta in a patient with Down syndrome and Alzheimer disease, Arch Neurol., 68, 11, pp. 1461-1466, (2011)
[53]  
Jennings D., Seibyl J., Sabbagh M., Lai F., Hopkins W., Bullich S., Et al., Age dependence of brain beta-amyloid deposition in Down syndrome: an [18F]florbetaben PET study, Neurology., 84, 5, pp. 500-507, (2015)
[54]  
Handen B.L., Cohen A.D., Channamalappa U., Bulova P., Cannon S.A., Cohen W.I., Et al., Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B, Alzheimers Dement., 8, 6, pp. 496-501, (2012)
[55]  
Annus T., Wilson L.R., Hong Y.T., Acosta-Cabronero J., Fryer T.D., Cardenas-Blanco A., Et al., The pattern of amyloid accumulation in the brains of adults with Down syndrome, Alzheimers Dement., 12, 5, pp. 538-545, (2016)
[56]  
Chiu M.J., Chen Y.F., Chen T.F., Yang S.Y., Yang F.P., Tseng T.W., Et al., Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early Alzheimer’s disease, Hum Brain Mapp., 35, 7, pp. 3132-3142, (2014)
[57]  
Dani A., Pietrini P., Furey M.L., McIntosh A.R., Grady C.L., Horwitz B., Et al., Brain cognition and metabolism in Down syndrome adults in association with development of dementia, NeuroReport., 7, 18, pp. 2933-2936, (1996)
[58]  
Rafii M.S., Wishnek H., Brewer J.B., Donohue M.C., Ness S., Mobley W.C., Et al., The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer’s disease biomarkers in down syndrome, Front Behav Neurosci., 9, (2015)
[59]  
Tapiola T., Soininen H., Pirttila T., CSF tau and Abeta42 levels in patients with Down’s syndrome, Neurology., 56, 7, pp. 979-980, (2001)
[60]  
Tamaoka A., Characterization of amyloid beta protein species in the plasma, cerebrospinal fluid and brains of patients with Alzheimer’s disease, Nihon Ronen Igakkai zasshi Jpn J Geriatr., 35, 4, pp. 273-277, (1998)
12345678